Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer
ConclusionThrough multigene panel testing, although many patients had druggable gene alterations, 10.8% of them received the recommended treatment. TMB-H was mainly observed in cervical/endometrial cancer, suggesting its potential as a therapeutic biomarker of immune checkpoint inhibitors. Furthermore, patients ’ prognosis and performance status should be considered before performing the test.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cervical Cancer | Endometrial Cancer | Genetics | Health Insurance | Insurance | Ovarian Cancer | Ovaries | Sarcomas | Study | Vaginal Cancer